Medical Services
CLDN18.2 CAR-T for selected advanced gastric cancers
Understand a newly approved option in China, its defined patient group and what specialist review would need to establish.
Clinical availability: Pending confirmation
What this helps you understand
Satri-cel is approved in China for CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at least two prior lines of treatment. It is not a treatment for every gastric cancer or every solid tumour.
Why explore care in China
The relevant development is access to a specific newly approved product in China. Participating teams, international patient eligibility and current supply must be confirmed with a receiving hospital.
Your next step
Contact NEXA to ask about information and collaboration for this emerging pathway. A specialist team would need to review pathology, biomarkers, previous treatment and health status before discussing suitability and care arrangements.
For referring and clinical partners
We welcome discussions with qualified gastrointestinal oncology and cell therapy teams about accurate information, patient selection, treatment support and cross-border follow-up.
NEXA CARE
Contact the Care team
Tell the Care team how to reach you. Please keep medical records and detailed health information for the protected Care process.